Joined May 2022
17 Photos and videos
I’m excited to launch the Longevity Biotech Atlas, a personal project mapping 700 organizations across the aging and longevity ecosystem. Longevity biotech is moving fast. A lot of the public narrative has centered on GLP-1s, peptides, biohacking, and consumer health optimization. But beneath that, a much deeper ecosystem is forming: companies, labs, investors, and non-profits working on core technologies that will enable fundamentally new forms of measurement and rejuvenation. The field is growing quickly, but it is still hard to answer basic questions: Who is building what? Which areas are crowded? Which technologies are underexplored? Where should founders, scientists, investors, and operators be paying attention? To help make the space easier to navigate, I synthesized public information on 700 organizations—ranging from therapeutics developers, diagnostics, investors, and more— into a single database. You can explore the atlas at the link in the comments. This is still an early version, and I’ll be adding more over time: new organizations, personal accounts, bookmarks, and better ways to track how the field is evolving. My hope is to build this out into a core tool for people trying to understand, build, fund, or work in longevity. If you’re interested in aging biology, biotech, investing, company formation, or the future of medicine, follow along. I’ll be sharing updates, maps of different subfields, and analyses of where the biggest opportunities and gaps may be. Let me know what you find useful!
30
41
336
22,696
Vitalist bay was a phenomenal experience last year! If you’re at all interested in aging this is the event you need to go to!
🧵 Elon: “Longevity is an extremely solvable problem” At Vitalist Bay (May 14 - May 17), we’re solving it! 1K pioneers, 100 speakers, 50 workshops, 40 activities, 5 critical health tests Join us to spark dozens of SpaceXs for longevity!
2
11
1,291
Rob Sheko retweeted
Big takeaway from looking through all the events: longevity, AI, and women's health are hot🔥. ARPA-H, the US govt's new $1.5bil/year granting agency, is on the ground at JPM looking for innovators shaping biotech's future. Lots of exciting events, see you all there! --Aevitas
1
6
438
Here's our guide to JPM week. Hope to see some of you at these events :)
That's right folks! It's JPM week, SF's biggest biotech event of the year. Here's our guide to some of the top events of the week (that you can still get into) 🧵
5
323
21 Dec 2025
What happens if you combine the TRIIM trial intervention with the recent DFI treatment Feng Zhang published? Both boosted different aspects of adaptive immune development and maintenance. The next step is clearly to put the two together!
1
1
2
285
21 Dec 2025
Fahy’s work seems to restore the structure of the thymus itself, while Friedrich’s showed increased common lymphoid progenitor proliferation and recruitment to the thymus.
158
6 Dec 2025
One year down, and what a journey its been! @AevitasHouse has been an incredible community of researchers and builders solving urgent challenges in human health. For 2026, we're expanding our support of projects in aging, bioengineering, and systems biology. Especially if you're early stage or new to SF, we'll help you find the right people and supporters for your project. If you've been looking for a hardcore, technical biotech community to call home, apply for our 2026 cohort!
🔥Announcing Aevitas 2026! 🔥 We had a phenomenal 2025, with companies ranging from brain tissue repair, large-scale biomarker analysis, stem cell manufacturing, and so much more! Are you a researcher, founder, or biotech builder? We have a home for you! Apply to join below 👇
3
11
1,069
14 Nov 2025
I’ll be one of the mentors for the workshop! And ofc excited for the debate 😁. Come hear some of my hot takes next week 🔥
AI x Longevity Pitch Workshop next week! Join NIMBLE and Aevitas for a showcase of cutting edge biotech companies followed by an Oxford style debate on the future of aging research, hosted at @FenwickWest. How will AI reshape the frontier of anti-aging biotech? Sign up below 👇
1
4
301
16 Oct 2025
You can see some of our analysis below! Current clinical tools struggle to identify patient-specific drivers of disease. The same chronic condition can have different biological causes across individuals. But if you have a healthy baseline of your biology, you can compare your before and after results to identify what's going wrong if you get sick. That's what motivated me to get my PMBCs sequenced, the first of several datapoints in my model of homeostasis. Really enjoyed highlighting the power of these research tools! 🔍 IMMUNE STATUS ASSESSMENT: • STEADY-STATE IMMUNITY: Low inflammatory cytokine expression suggests healthy, non-activated immune status • ACTIVE SURVEILLANCE: High chemokine expression indicates ongoing immune patrol and tissue surveillance • MEMORY RESPONSES: Strong antibody production suggests established immunological memory • CYTOTOXIC READINESS: NK and T cell activation markers indicate prepared anti-viral/anti-tumor responses • Robust memory T cell trafficking (RANTES dominance) T CELL COMPARTMENT ANALYSIS: • Balanced CD4 /CD8 T cell ratio (0.86:1) indicates healthy immune status • High proportion of memory T cells suggests prior antigen exposure • MAIT cells (6.5%) - important for mucosal immunity and pathogen response • Regulatory T cells (3.0%) - normal proportion for immune homeostasis B CELL MATURATION STATUS: • Balanced memory:naive B cell ratio (1.07:1) indicates active immune responses • Age-associated B cells present but low (1.0%) - normal for healthy adults • No detectable plasma cells suggests no active inflammatory response INNATE IMMUNE LANDSCAPE: • NK cells show CD16 dominance (8.8:1 ratio) - typical cytotoxic profile • Classical monocytes predominate (4.85:1) - normal circulating pattern • Low DC2 and pDC populations consistent with steady-state conditions OVERALL IMMUNE PROFILE: • T cell dominance (76.9%) typical of healthy PBMCs • No signs of immune activation or inflammatory states • Diverse immune cell repertoire with all major populations represented • Quality metrics suggest high-quality sample with minimal technical artifacts
Great conversation at our Tech Week event with @imyoohealth and @kepler_ai_ on combining AI with advanced biomonitoring to create robust pictures of health and disease. If you want to learn more, keep an eye out for our next monthly meetup on these topics!
1
3
500
5 Oct 2025
I’ll be analyzing my own blood proteomics and single cell RNA data! A lot of these tools are available to researchers but haven’t made it to the clinic. We’re working on bridging that gap and unlocking new dimensions of personalized healthcare.
This Tuesday: We're co-hosting a special event on the Frontiers of Personalized Biomarkers as part of @a16z's @Techweek_. With @imyoohealth and @kepler_ai_, we'll demonstrate how multi-omics and AI can reshape healthcare and the future of data-driven bioenhancement. Info below
2
6
665
Rob Sheko retweeted
biologists continue to mistake single-cell technical sampling noise for meaningful cellular heterogeneity. the apparent sparsity of single-cell data is due largely to technical artifacts like transcript capture and sequencing depth--if there are hundreds of thousands of transcripts per cell but you sequence only 5-10k unique molecules, of course you get mostly zeroes in any given cell. pseudo-bulking makes this clear: when you aggregate these noisy single cell samples, the vast majority of the genome shows expression greater than zero this is because the entire genome is being pervasively (yet stochastically) transcribed across nearly all cell types, including terminally differentiated cells (with a few obvious exceptions, e.g. enucleated red blood cells, spermatozoa, etc). hence you should expect to find at least one copy of nearly every transcript if you sample a single cell deeply enough over time it is the *relative* or *ranked* differences in expression compared to this low-level baseline that dictate cellular identity and function yet this pervasive transcription extends to retrotransposons, heterochromatin, and other supposedly "silenced" regions of the genome--all of which are systematically discarded in most standard processing pipelines. stare at the raw .fastq for long enough and this becomes obvious thus, this pervasive genome-wide transcription has implications not only for how we train virtual cell models on single-cell RNA count data, but for our understanding of cellular biology as a whole: to truly plumb the depths of the cell, we must venture beyond the reference genome into transcriptional terra incognita, where we will encounter eldritch species of non-coding RNAs that may throw into question much of what we know about the biology of the cell
"Only ~0.02%-3.1% of [a cell's] genome" is being transcribed at any given moment. Other interesting takeaways from this new paper: > If you pool together a bunch of cells of the SAME type (like primary immune cells from a mouse's spleen), and you measure the transcription for each of them, you'll find that ~67% of the genome is active collectively. But at a SINGLE cell level, only like 0.04% of the genome is active. There is huge heterogeneity between cells, even of the same type. This heterogeneity disappears when we do bulk RNA-seq and measure cells together. > About 31% of a cell's transcription comes from known protein-coding genes. The rest of transcription happens in regions that don't make proteins. In other words, more "non-coding" DNA is transcribed than "coding" DNA. > There is a surprising disconnect between RNA production & decay at the single-cell level. If you look at thousands of cells together, the rate of RNA production (how fast genes are transcribed) usually matches the rate of RNA decay (how fast old transcripts are degraded). This makes sense, because cells presumably would want to keep a fairly steady balance of RNA levels. But when scFLUENT-seq was used to look at individual cells, this "rule" broke down! For a given mRNA, some cells were making a lot of new copies even if old copies weren’t being degraded much, while other cells had the opposite. So transcription and decay don't seem to be tightly matched within a single cell at a given time after all. The balance between production decay is only true in bulk.
19
112
813
90,274
Rob Sheko retweeted
Love this screenshot - formal, rational systems are great because they are very precise - but their fundamental incompleteness pushes us into the irrational wilderness if we want to find truth & bring it back inside
20
19
264
10,276
29 Aug 2025
You know how glp1s have a lot of anecdotal evidence on curing addictions? What if the NLRP3 inhibitors everyone is working on end up fixing ADHD?
1
6
242
26 Aug 2025
Both axolotls and naked mole rats don’t undergo thymic involution, and both have negligible senescence with age…
Favorite talk from @ARDD_Meeting day 1 was Maximina Yun's thorough look at aging in axolotls. These guys live ~10 years and regenerate limbs throughout. How and why they die is what she tried (and failed) to discover: - They don't have increased mortality late in life. - She couldn't detect any senescent cells by standard stains. - No telomere shortening. - Functional stem cells obviously. - Most interesting, their thymus doesn't involute. In ~all other animals, thymic cells are replaced by fat (by age 40 it's gone in humans) meaning limited education of new immune cells. In axolotls she sees upregulation of PPARG suggesting initiation of fat conversion, but no actual transition. Now doing an extensive -omics exploration of thymus throughout life (collab w @altos_labs), excited to see this.

ALT Happy Smile GIF

8
276
24 Aug 2025
Abundant non-invasive stem cells seems game changing 👀
24 Aug 2025
Stoked to be speaking at MIT spreading awareness of stem cells for women’s health ⁦@MIT⁩ ⁦@medialab
1
1
6
299
14 Aug 2025
I recently got three wonderful pet rats and I want to teach them how to drive. Does anyone know how we can make a car like in this video?
1
1
13
490
14 Aug 2025
This is the article for context: abc7news.com/amp/post/resear… Seems fun

5
130
7 Aug 2025
We're hosting this tn!
Interested in the cutting edge of neurobiology? We're hosting a Frontiers of Neuroscience Salon this Wednesday! Hear three experts present on BCI, cell replacement, and hidden networks of regulation in the brain. Sign up below 🧠👇
6
261